Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
From 1/10/19 lol
I ve been long gone lol
Uh oh.... and might be happening on that other Q stock soon...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148913151
ARLZQ: Bankruptcy PLAN effective. All shares cancelled.
https://otce.finra.org/otce/dailyList?viewType=Deletions
Constant dumping the last 2 days. Probably insiders unloading before the announcement that shareholders will not receive a settlement after all
ARLZQ...006...Gap filled today on the 100% move...http://schrts.co/cKdnfHuM...
ARLZQ...003...Item 2.01 Completion of Acquisition or Disposition of Assets.
On March 6, 2019, Old API Wind-down Ltd. (f/k/a Aralez Pharmaceuticals Inc.) (the “ Company ”) completed its previously announced sale of the Company’s TOPROL-XL® franchise to Toprol Acquisition LLC (“ Acquisition Sub ”), for approximately $130,000,000 as a credit bid (the “ Toprol Sale ”), pursuant to the Asset Purchase Agreement (the “ APA ”), dated September 18, 2018, by and among Acquisition Sub and Aralez Pharmaceuticals Trading DAC, a subsidiary of the Company. Acquisition Sub is owned by the secured lenders of the Company, Deerfield Private Design Fund III, L.P. and Deerfield Partners, L.P.
The foregoing description of the Toprol Sale does not purport to be complete and is qualified in its entirety by the APA, which is incorporated herein by reference to Exhibit 2.3 to the Company’s Form 8-K filed with the Securities and Exchange Commission on September 19, 2018.
https://www.otcmarkets.com/filing/html?id=13282997&guid=296tUK_WErCbYth
Just heard from legal reps. Their will be no distribution to shareholders and no reissue of stock to shareholders. Check with your tax person for loss declaration. I'm out @ 71,000 shares and in my opinion the way it unfolded was a tad dishonest.
ARLZQ...004...Nice move to .0115 followed by a dip to the .002 range which left an open gap in the .006 range that should fill...
Chart...http://schrts.co/eQegvnDT
https://www.otcmarkets.com/filing/html?id=13162447&guid=dBktUn0Vr9ul-th
Effective as of January 18, 2019, Sanjay Subramanian, 43, the Company’s current Treasurer, will assume the role of Chief Financial Officer. Prior to joining the company, Mr. Subramanian was the Director of Treasury at Bausch Health Companies. Mr. Subramanian started his finance career at General Motors Co. where he held various positions before leaving as the Treasurer of GM Korea.
Effective as of January 31, 2019, Christopher Freeland, 40, the Company’s current General Counsel, will also assume the role of Chief Operating Officer. Prior to being appointed as the Company’s General Counsel, Mr. Freeland was the Company’s Associate General Counsel. Prior to joining the Company, Mr. Freeland was an Associate General Counsel at American International Group. Mr. Freeland started his legal career as a corporate associate at Willkie Farr & Gallagher LLP.
Based on volume i d think bad?
Important Docket out yesterday "Notice of Hearing / Notice of Toprol Sale Hearing filed by Paul V. Shalhoub on behalf of Aralez Pharmaceuticals US Inc., et al.."
Remember that TOPROL valued $ 130 Millions.
https://cases.primeclerk.com/Aralez/Home-DocketInfo
11 Dockets out yesterday : https://cases.primeclerk.com/Aralez/Home-DocketInfo
$ARLZQ: NEWS... Intercept acquires Bezafibrate from Aralez-Pharma
Major HealthCare conference happening this week.....
37th Annual J.P. Morgan Healthcare Conference
https://globenewswire.com/news-release/2019/01/07/1681125/0/en/Intercept-Announces-NASH-and-PBC-Program-Updates.html
In addition, Intercept announced that it has acquired from Aralez Pharmaceuticals Inc. its license to develop and commercialize bezafibrate in the U.S., its IND on file with the FDA and other associated regulatory documentation, and a non-exclusive license to certain of Aralez’s intellectual property. Bezafibrate, a pan-peroxisome proliferator-activated receptor (PPAR) agonist that has been studied in PBC, is not approved in the U.S. for any indication. Intercept intends to initiate a Phase 2 study to evaluate the efficacy, safety and tolerability of bezafibrate in combination with OCA in patients with PBC, with the longer term goal to develop and seek regulatory approval for a fixed dose combination regimen in this indication and potentially other liver diseases.
“We are pleased to have acquired the U.S. rights to bezafibrate and look forward to studying it in combination with OCA as a potential treatment for progressive non-viral liver diseases. Based on the potential benefits of combining bezafibrate with OCA in PBC, we will initially study the combination in this indication,” said Christian Weyer, M.D., M.A.S., Intercept's Executive Vice President, Research & Development.
Go $ARLZQ
TOPROL-XL® Franchise transaction valued at U.S.$130 million will open soon more eyes :)
"The Company and certain of its affiliates continue to seek approval of the U.S. Bankruptcy Court for the sale of its TOPROL-XL® Franchise to its secured lender, certain funds managed by Deerfield Management Company, L.P. ("Deerfield"), in a transaction valued at U.S.$130 million "
Agree. Higher prices coming. Longs are holding.
$ARLZQ: Minimal selling.... Next Leg up coming
This is a very good base level here at $0.007
Massive break higher is on tap for Aralez.
GO $ARLZQ
Exact same trading patterns last 2 days. Drop thru the bid on low (under 100k) volume then slowly ramp up the bid (currently 0.0059). Just a patience play. Another extension on the docket gives them more time to play games, I guess. But you never know when they will pull the buy trigger.
$ARLZQ: I see $0.15/sh coming
But then again... thats just me :)
Currently at $0.0074
GO $ARLZQ
2 new filings in the docket for 01/03/2019
https://cases.primeclerk.com/Aralez/Home-DocketInfo
Docket# 419
Notice of Adjournment of Hearing / Notice of Cancellation of January 10, 2019 Omnibus Hearing filed by Paul V. Shalhoub on behalf of Aralez Pharmaceuticals US Inc., et al..
01/03/2019
Docket #418
Order, signed on 1/3/2019, Authorizing Continued Extension of Deadline to Comply with Section 345(b) of the Bankruptcy Code on an Interim Basis. (related document(s)395)
01/03/2019
ARLZQ possibly. 53% now after 430% yesterday
fairly low volume, next big Q bro?
- Armin
Amateur hour(s) over. Penny bid now. Nobody wanted to sell into their crappy lowball bids all day.
0087 X 0099 now. 5 mil still showing on the bid
About time but they still get no love so far. Let's see that 5 mil move up to 0.009 bid.
Stocktwits arlzchapter11 message board link
https://stocktwits.com/r/arlzchapter11/
162k volume all day so far. Huge bids have been stacked up 0.004, 0.005, 0.0055 and now 0.0057. They are getting no love.
Also notice the ask has been mysteriously thinning as well. 0.0086 had 50,000 taken out by just 1,100. 0.0088 ask just disappeared. This is so thin.
Bids stacked up all day barely any sales. Come in market makers, make a market !
What is the thought on commons here?
Bid creeping up 0.0055 now. Still not a seller in the house. Hit the ask champs!
Very active case Aralez Pharmaceuticals US Inc. (18-12425)
Yesterday January 02, 2019 got 2 dockets added
https://cases.primeclerk.com/Aralez/Home-DocketInfo
CDEL 300,000 @0.0052
ETRF 40,000 @0.0052
CSTI 100,000 @0.005
NITE 5,000,000 @0.004
None of them can get a fill.
5 Millions shares bidder @ 0.004 (NITE)
Hit 005 I bet you see him.
Prop bid as the 5 milly bidder is gone
Imo
Are commons done?
5M bid and he's not getting filled. Ask smacking to come shortly.
We shall see...but I am in...
chart is a beauty ,definite reversal to bull
Followers
|
25
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
470
|
Created
|
02/05/16
|
Type
|
Free
|
Moderators |
Aralez Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada, Ireland, and the United States. It engages in acquiring, developing, and commercializing products primarily in cardiovascular disease, pain, and other specialty areas. It offers Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia; Cambia, a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks; Fiorinal and Fiorinal C for the relief of tension type headaches; Soriatane, a retinoid, an aromatic analog of vitamin A for the treatment of severe psoriasis and other disorders of keratinization; and Bezalip SR, a pan-peroxisome proliferator-activated receptor activator to treat hyperlipidemia, as well as to increase insulin sensitivity and decrease blood glucose levels for the patients with metabolic syndrome. It also markets NeoVisc, a sodium hylauronic solution; Uracyst, a sodium chondroitin sulfate; Durela, a tramadol hydrochloride; Proferrin, a heme iron polypeptide; Resultz, a isopropyl myristate; Collatamp G, a collagen-gentamycin; and a portfolio of eight products targeted for the areas of gastroenterology and women?s health. In addition, it develops YOSPRALA 81/40 and 325/40 for secondary prevention of cardiovascular and cerebrovascular disease in patients at risk for gastric ulcers, which have completed Phase III clinical development in the United States; and Bilastine, an antihistamine drug for the treatment of allergic rhinoconjunctivitis and urticaria. Further, its out-licensed products include VIMOVO for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers; and Treximet, a migraine medicine. The company is headquartered in Milton, Canada.
Aralez Pharmaceuticals Inc.’s ISS Governance QualityScore as of March 2, 2017 is 6. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 4; Compensation: 9.
151 Steeles Avenue East
Milton, ON L9T 1Y1
Canada
905-876-1118
http://www.aralez.com
Sector:
Industry:
Full Time Employees:
Name | Title | Pay | Exercised | Age |
---|---|---|---|---|
Mr. Adrian Adams | Chief Exec. Officer and Director | 1.02M | N/A | 66 |
Mr. Andrew I. Koven | Pres and Chief Bus. Officer | 683.18k | N/A | 59 |
Mr. Scott J. Charles | Chief Financial Officer | 653.07k | N/A | 42 |
Mr. Mark A. Glickman | Chief Commercial Officer | 504.94k | N/A | 51 |
Mr. John E. Barnhardt CPA | Principal Accounting Officer and VP of Fin. & Admin. | N/A | N/A | 67 |
SHARE THIS ARTICLE
-First Quarter 2017 Net Revenues of $26.0 Million-
-Cost Savings Plan Expected to Reduce 2017 Expenses by $23.0 Million; Improved 2017 Adjusted EBITDA Guidance-
-Currently Implementing a Bold Program Aimed at Allowing All Patients to Access Yosprala for Only $10.00 Per Month-
MISSISSAUGA, Ontario, May 9, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) (Aralez or the Company) today announced financial results for the first quarter ended March 31, 2017. The Company also highlighted certain recent corporate and commercial achievements. All figures are in U.S. dollars.
"We are pleased to report a solid first quarter of 2017, together with important updates to our business addressing a number of the challenges we face," said Adrian Adams, Chief Executive Officer of Aralez. "We are making a bold and significant change to our pricing strategy for Yosprala® aimed at allowing all patients to access the product for only $10.00 per month. In addition, we continue to implement our cost savings plan to further improve our cost structure and balance sheet to maximize and preserve our financial flexibility. Our updated financial guidance for 2017 reflects our commitment to reaching break-even on an Adjusted EBITDA basis this year. We also continue to opportunistically look at business development opportunities with a strong focus on value creating and transformative M&A with the goal of enhancing shareholder value."
Company Highlights:
"Deerfield Partners remains fully supportive of Aralez and its management team as the company navigates its way through recent challenges," said James Flynn, Managing Partner at Deerfield. "We are encouraged by the new pricing strategy for Yosprala and the prospects for Zontivity."
Cost Savings Initiatives
The Company previously announced in April 2017 that it had begun implementing cost savings initiatives as part of the Company's ongoing objective to maximize value from its assets and preserve financial flexibility. The total expected operating expense reduction in 2017 of approximately $23.0 million includes the previously announced 32% reduction in its U.S. sales force, which is expected to yield 2017 savings of approximately $5.5 million ($7.5 million on an annual basis), a decrease of approximately $9.0 million in 2017 commercial spend, which primarily relates to non-direct marketing spend on Yosprala, and decreased 2017 departmental expenses across the business of approximately $8.5 million. While Aralez has made significant reductions to its expenses, the Company plans to invest an additional $7.0 million to support a successful phased launch of Zontivity that commenced on April 24, 2017, which the Company views as an increasingly attractive opportunity. The Company also continues to assess various business development opportunities with the goal of providing improved cash flow and an enhanced platform for creating value.
First Quarter 2017 Financial Results
Aralez's financial results for the three months ended March 31, 2016 include the operations of Tribute Pharmaceuticals Canada Inc. (Tribute) from February 5, 2016, the closing date of the Pozen and Tribute merger transaction (the Merger), through March 31, 2016, but do not include the results of Zontivity or Toprol-XL and its currently marketed authorized generic (the Toprol-XL franchise) as these acquisitions were completed on September 6, 2016 and October 31, 2016, respectively. Aralez's financial results for the three months ended March 31, 2017 include the results of Tribute, Zontivity and the Toprol-XL franchise.
Total revenues for the three months ended March 31, 2017 were $26.0 million compared to $8.1 million for the three months ended March 31, 2016. Net product revenues of $6.7 million for the three months ended March 31, 2017 primarily related to the product portfolio acquired with the acquisition of Tribute as well as net product revenues from Yosprala and Fibricor®. Other revenues of $19.3 million for the three months ended March 31, 2017 were comprised of net revenues of $15.6 million from the acquisitions of the Toprol-XL franchise and Zontivity, which are recorded net of related cost of product revenues and fees paid during the respective transition service periods, and Vimovo® royalties of $3.7 million. Pursuant to the Company's agreement with Horizon in the U.S., subject to certain conditions described in our public filings, Aralez is guaranteed a quarterly minimum royalty amount (calculated based on a minimum annual royalty of $7.5 million), which was reflected in the Company's first quarter results. Net product revenues of $3.6 million for the three months ended March 31, 2016 related to the Tribute product portfolio acquired in the Merger, which was completed on February 5, 2016. Other revenues of $4.5 million for the three months ended March 31, 2016 were comprised solely of Vimovo royalties.
Cost of product revenues were $2.8 million for the three months ended March 31, 2017 compared to $2.5 million for the three months ended March 31, 2016. The increase related primarily to costs of product revenues for the full quarter in 2017 from the Company's product portfolio that was acquired as part of the Merger in February 2016.
SG&A expenses were $30.8 million for the three months ended March 31, 2017 compared to $37.5 million for the three months ended March 31, 2016. The decrease in SG&A expenses was primarily driven by costs related to the Merger in the prior year of approximately $19.4 million, partially offset by increased costs related to the build out of our U.S. sales force in 2016 and increased promotional expenses in the U.S. during the first quarter of 2017.
R&D expenses for the three months ended March 31, 2017 were $0.1 million compared to $4.4 million for the three months ended March 31, 2016. The decrease related primarily to higher costs incurred in the first quarter of 2016 for Yosprala in advance of its U.S. approval in September 2016.
Amortization of intangible assets of $8.5 million for the three months ended March 31, 2017 related to the acquisitions of Tribute, Zontivity and the Toprol-XL franchise. Amortization of intangible assets for the three months ended March 31, 2016 of $1.3 million related solely to the acquisition of Tribute.
The change in fair value of contingent consideration of $4.4 million for the three months ended March 31, 2017 related to accretion for the Toprol-XL franchise and Zontivity acquisitions. There was no expense related to fair value changes in contingent consideration for the three months ended March 31, 2016.
Interest expense of $6.7 million for the three months ended March 31, 2017 was primarily attributable to the borrowing of $200 million under the Company's credit facility in the fourth quarter of 2016 in connection with the acquisitions of Zontivity and the Toprol-XL franchise and $75 million convertible notes. Interest expense of $0.3 million for the three months ended March 31, 2016 related to the $75 million convertible notes.
Other income, net for the three months ended March 31, 2017, was $0.4 million compared to $4.8 million for the three months ended March 31, 2016, a decrease of $4.4 million. The decrease principally related to a $4.6 million decrease in the fair value of the warrants liability acquired from Tribute during the prior year, offset by a $0.3 million gain from the sale of a building in London, Ontario during the three months ended March 31, 2017.
The net loss for the three months ended March 31, 2017 was $27.5 million, or $0.42 loss per share on a fully diluted basis, compared to a net loss for the three months ended March 31, 2016 of $33.8 million, or $0.73 loss per share on a fully diluted basis.
Adjusted EBITDA was ($3.6) million for the three months ended March 31, 2017 compared to Adjusted EBITDA of ($11.1) million for the three months ended March 31, 2016.
Balance Sheet
As of March 31, 2017, approximately 65.8 million of the Company's common shares were issued and outstanding and the Company had cash and cash equivalents of approximately $73.7 million.
Updated 2017 Guidance
Aralez's estimates are based on projected results of the Company for the year ending December 31, 2017 and reflect management's current beliefs and expectations about, among other things, prescription trends, competition, pricing levels, inventory levels, and anticipated future events. The Company's guidance on Adjusted EBITDA includes, among other things, costs to support the commercialization efforts with respect to Yosprala, Zontivity and the Canadian product portfolio as well as costs to support the global corporate structure. It excludes share-based compensation expense and certain discrete costs, including merger and product acquisition-related expenses. See "Use of Non-GAAP Financial Measures" below.
For the year ending December 31, 2017, assuming, among other factors more particularly set out in "Cautionary Note Regarding Forward-Looking Statements" below, the Company currently expects:
See the table below for a comparison of the Company's original 2017 guidance compared to the updated 2017 guidance:
Measure | 2017 Original Guidance | 2017 Updated Guidance |
Net Revenues | $80 million to $100 million | $80 million to $100 million |
Adjusted EBITDA | $(25) million to $(10) million | $(5) million to $5 million |
First Quarter Results Webcast
Aralez will host a webcast this morning, May 9, 2017 at 9:00 a.m. ET to present results for the first quarter 2017. The webcast can be accessed live and will be available for replay at www.aralez.com.
Conference Call Details
Date: Tuesday, May 9, 2017
Time: 9:00 a.m. ET
Dial-in (U.S.): 877-407-8037
Dial-in (International): 201-689-8037
About Aralez Pharmaceuticals Inc.
Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) is a global specialty pharmaceutical company focused on delivering meaningful products to improve patients' lives while creating shareholder value by acquiring, developing and commercializing products primarily in cardiovascular, pain and other specialty areas. Aralez's Global Headquarters is in Ontario, Canada, the U.S. Headquarters is in Princeton, New Jersey and the Irish Headquarters is in Dublin, Ireland. More information about Aralez can be found at www.aralez.com.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |